Automatic High-throughput Hybridoma Antibody Molecular Discovery Platform
Single B Cell Screening Platform
ADC Platform
Bispecifics Platform
Clinical Trials
Papers
AdvantagesBased on the IDDC™ platform of Mabwell, 9MW2821 reveals the advantages of homogenous structure, high purity, with simple production process. 9MW2821 has achieved positive clinical outcomes in multiple tumor indications.
Mechanism of ActionBy specifically binding to the target ST2, 9MW1911 blocks the activation of the ST2-mediated signaling pathway induced by cytokine IL-33, inhibiting inflammatory reactions and achieving therapeutic effects in multiple auto-immune diseases.
AdvantagesCompared to small molecules, peptides, and gene therapy drugs or drug candidates, 9MW3011 reveals the advantages of a long half-life, great safety profile, and reduced treatment costs. The scarcity of effective therapies for related indications can position itself as a promising macromolecular drug candidate for regulating iron homeostasis globally.
Mechanism of Action9MW3811 effectively blocks the activation of IL-11 downstream signal pathway being developed for fibrosis and oncology. Preclinical study result has been published on AACR.
Mechanism of ActionAfter oral intake into the human body, 1MW5011 can be rapidly converted into N-butyrylglucosamine in the body and enriched in the joint cavity, which improves cartilage destruction in osteoarthritis patients by increasing the anabolic metabolism and decreasing the catabolic metabolism of articular cartilage, and indirectly improves the bioavailability of N-butyryl glucosamine, and thus exerts a therapeutic effect on osteoarthritis.
UC combination (1L)
UC monotherapy (2L+)
CC monotherapy (2L/3L)
ESCC
TNBC combination (1L)
TNBC monotherapy
Other solid tumors
Advanced solid tumor
Advanced solid tumor
Giant cell tomor of bone*
Febrile neutropenia caused by anti-cancer drugs*
Malignant advanced tumor
Malignant advanced tumor
8 indications (Rheumatoid arthritis, etc. )*
COPD, asthma & atopic dermatitis
Idiopathic pulmonary fibrosis
Treatment of postmenopausal women with osteoporosis at high risk for fracture
Osteoarthritis
Diabetic macular edema, neovascular (wet) age-related macular degeneration
Neovascular (wet) age-related macular degeneration
Iron overload disorders including β-thalassemia, polycythemia vera
Staphylococcus aureus infection
Mabwell's automatic high-throughput hybridoma antibody molecular discovery platform, equipped with international advanced equipment, has an independently integrated workstation system, and is combined with a variety of animal immune technologies, efficient and stable hybridoma electrofusion technology, serum-free hybridoma suspension culture technology, real-world flow screening technology and many other underlying technologies. Meanwhile, in the antibody engineering transformation optimization system composed of computer-aided design and various display technologies, the platform adds physical and chemical stability indicators such as antibody expression characteristics, molecular binding epitope and hydrophobicity to ensure that the obtained innovative molecules meet the needs of industrialization. In addition, the platform also has a unique affinity mature transformation technology. On the basis of maintaining the activity of antibody molecules, it can greatly improve the binding affinity of antibody molecules, effectively improving the probability of druggability of innovative molecules.
01The target development scope is wider and the immune success rate is improved from the source.
02Highly efficient, stable and reproducible hybridoma electrofusion technique, increasing the hybridoma screening abundance, and being conducive to obtaining candidate antibody molecules.
03Workflow integrating manipulator and high-throughput antibody sorting equipment.
04Serum free hybridoma suspension culture significantly accelerated the cloning and screening and reduce the incidence of false positive.
05Antibody multi property evaluation system for cell stereoepitope level.
Mabwell's high efficiency B lymphocyte screening platform is based on the direct separation of antigen-specific B lymphocytes from the spleen of immunized animals and human peripheral blood, and the antigen-specific B lymphocytes were enriched and the primary B lymphocytes were cloned and expanded by using the proprietary technology of efficient panning and clonal amplification. The use of efficient panning technology has achieved the screening of one hundred thousand B lymphocytes that can specifically bind to antigen from one hundred million B lymphocytes, the positive rate of secreted antibody binding to antigen is more than 90%, which significantly improves the discovery rate of high affinity antibody molecules, reduces the loss of positive B lymphocytes and improves the abundance of candidate antibodies in the process of panning. The high affinity antibody gene that is difficult to obtain by conventional cell fusion can be obtained by using the high-efficiency B lymphocyte screening technology, thus, better candidate antibody molecules are obtained, which enriches the technical means of new antibody molecule discovery.
01The positive rate of antigen-specific B lymphocytes was significantly increased.
02Naturally stable antibody sequences can be obtained by screening.
03The antibody molecular screening process has high fidelity, and the operating samples can be frozen for a long time.
04Antibody molecular screening has strong pertinence and low research cost.
05The technique is highly versatile and can achieve cross-species adaptation.
Mabwell's ADC Platform is established based on two 3rd-generation antibody conjugation technologies. Both technologies have submitted patent applications. The coupling process is reliable and the coupling product is more uniform and better than the ADC developed by other bridging fixed-point technologies. Compared with other types of antibody-drug conjugates, it has better pharmacokinetics, pharmacological and toxicological characteristics.
01Two different coupling technologies can develop ADC drugs for different types of high activity small molecule drugs.
02The two different coupling techniques are applicable to the common antibody IgG1, and the natural antibody sequence can be used directly.
03The conjugates have excellent uniformity, simplified process, easy quality control, and can significantly expand the therapeutic window in the process of use.
Interchain-Disulfide Drug Conjugate (IDDC™) platform IDDC™ is a next generation ADC site-specific conjugation technology platform independently developed by Mabwell. It is composed of multiple systematized core patent technologies including site-specific conjugate process DARfinity™, special designed linker IDconnect™, novel payload Mtoxin™, and conditional release structure LysOnly™, which improves structural homogeneity, quality stability, pharmacodynamics and tolerability of the ADC products.
Site-specific conjugation technology
Increasing structural homogeneity of drug
Stable interchain disulfide bonds
Enhancing the stability of ADC during metabolism
Efficient and stable release structure
Showing great stability / Stable in the bloodstream
Dependent on specific enzymes for degradation
Reducing off-target toxicity
Novel topoisomerase inhibitors
Mabwell's Bispecific Antibody Platform has three mature design schemes of Fc fusion protein like double antibodies in the form of common light chain, heterodimer structure and head tail structure, which can be optimized according to the characteristics of different double antibodies/proteins, The key common problems of engineering cell line screening, production process and quality control were solved, which laid a foundation for the comprehensive expansion of double antibody technology.
01Differential design based on the molecular characteristics and functional requirements of the antibody reduces the difficulty of process development and quality control in the development stage and even the commercial production stage.
02Take design as the source to solve the difficulties in process development, improve the stability of antibody molecules, improve the expression in the culture process.
03Significantly reduce the production cost of bispecific/bifunctional antibodies, make the products more clinically accessible after commercialization.
Automatic High-throughput Hybridoma Antibody Molecular Discovery Platform
Single B Cell Screening Platform
ADC Platform
Bispecifics Platform
Automatic High-throughput Hybridoma Antibody Molecular Discovery Platform Mabwell's automatic high-throughput hybridoma antibody molecular discovery platform, equipped with international advanced equipment, has an independently integrated workstation system, and is combined with a variety of animal immune technologies, efficient and stable hybridoma electrofusion technology, serum-free hybridoma suspension culture technology, real-world flow screening technology and many other underlying technologies. Meanwhile, in the antibody engineering transformation optimization system composed of computer-aided design and various display technologies, the platform adds physical and chemical stability indicators such as antibody expression characteristics, molecular binding epitope and hydrophobicity to ensure that the obtained innovative molecules meet the needs of industrialization. In addition, the platform also has a unique affinity mature transformation technology. On the basis of maintaining the activity of antibody molecules, it can greatly improve the binding affinity of antibody molecules, effectively improving the probability of druggability of innovative molecules.
01The target development scope is wider and the immune success rate is improved from the source.
02Highly efficient, stable and reproducible hybridoma electrofusion technique, increasing the hybridoma screening abundance, and being conducive to obtaining candidate antibody molecules.
03Workflow integrating manipulator and high-throughput antibody sorting equipment.
04Serum free hybridoma suspension culture significantly accelerated the cloning and screening and reduce the incidence of false positive.
05Antibody multi property evaluation system for cell stereoepitope level.
Single B Cell Screening Platform Mabwell's high efficiency B lymphocyte screening platform is based on the direct separation of antigen-specific B lymphocytes from the spleen of immunized animals and human peripheral blood, and the antigen-specific B lymphocytes were enriched and the primary B lymphocytes were cloned and expanded by using the proprietary technology of efficient panning and clonal amplification. The use of efficient panning technology has achieved the screening of one hundred thousand B lymphocytes that can specifically bind to antigen from one hundred million B lymphocytes, the positive rate of secreted antibody binding to antigen is more than 90%, which significantly improves the discovery rate of high affinity antibody molecules, reduces the loss of positive B lymphocytes and improves the abundance of candidate antibodies in the process of panning. The high affinity antibody gene that is difficult to obtain by conventional cell fusion can be obtained by using the high-efficiency B lymphocyte screening technology, thus, better candidate antibody molecules are obtained, which enriches the technical means of new antibody molecule discovery.
01The positive rate of antigen-specific B lymphocytes was significantly increased.
02Naturally stable antibody sequences can be obtained by screening.
03The antibody molecular screening process has high fidelity, and the operating samples can be frozen for a long time.
04Antibody molecular screening has strong pertinence and low research cost.
05The technique is highly versatile and can achieve cross-species adaptation.
ADC Platform Mabwell's ADC Platform is established based on two 3rd-generation antibody conjugation technologies. Both technologies have submitted patent applications. The coupling process is reliable and the coupling product is more uniform and better than the ADC developed by other bridging fixed-point technologies. Compared with other types of antibody-drug conjugates, it has better pharmacokinetics, pharmacological and toxicological characteristics.
01Two different coupling technologies can develop ADC drugs for different types of high activity small molecule drugs.
02The two different coupling techniques are applicable to the common antibody IgG1, and the natural antibody sequence can be used directly.
03The conjugates have excellent uniformity, simplified process, easy quality control, and can significantly expand the therapeutic window in the process of use.
Interchain-Disulfide Drug Conjugate (IDDC™) platform IDDC™ is a next generation ADC site-specific conjugation technology platform independently developed by Mabwell. It is composed of multiple systematized core patent technologies including site-specific conjugate process DARfinity™, special designed linker IDconnect™, novel payload Mtoxin™, and conditional release structure LysOnly™, which improves structural homogeneity, quality stability, pharmacodynamics and tolerability of the ADC products.
Site-specific conjugation technology
Increasing structural homogeneity of drug
Stable interchain disulfide bonds
Enhancing the stability of ADC during metabolism
Efficient and stable release structure
Showing great stability / Stable in the bloodstream
Dependent on specific enzymes for degradation
Reducing off-target toxicity
Novel topoisomerase inhibitors
Bispecifics Platform Mabwell's Bispecific Antibody Platform has three mature design schemes of Fc fusion protein like double antibodies in the form of common light chain, heterodimer structure and head tail structure, which can be optimized according to the characteristics of different double antibodies/proteins, The key common problems of engineering cell line screening, production process and quality control were solved, which laid a foundation for the comprehensive expansion of double antibody technology.
01Differential design based on the molecular characteristics and functional requirements of the antibody reduces the difficulty of process development and quality control in the development stage and even the commercial production stage.
02Take design as the source to solve the difficulties in process development, improve the stability of antibody molecules, improve the expression in the culture process.
03Significantly reduce the production cost of bispecific/bifunctional antibodies, make the products more clinically accessible after commercialization.
Indications: treatment of adults and skeletally mature adolescents (defined as at least 1 mature long bone and weighing ≥ 45 kg) with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Indications: treatment of postmenopausal women with osteoporosis at high risk for fracture. In postmenopausal women with osteoporosis, MAILISHU reduces the incidence of vertebral, nonvertebral, and hip fractures.
Indications: rheumatoid arthritis, ankylosing spondylitis (AS), psoriasis, crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis (pJIA), pediatric plaque psoriasis, pediatric crohn’s disease
